Tourmaline Bio
Financials
Estimates*
USD | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Revenues | - | - | - | 10.0m | 12.0m |
% growth | - | - | - | - | 20 % |
EBITDA | (19.7m) | (45.4m) | - | - | - |
Profit | (19.7m) | (42.1m) | (78.1m) | (99.0m) | (124m) |
% profit margin | - | - | - | (990 %) | (1035 %) |
EV / revenue | - | - | - | -1.4x | 10.0x |
EV / EBITDA | - | -11.7x | - | - | - |
R&D budget | 17.5m | 32.4m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Seed | |
* | $112m | Series A | |
N/A | N/A | IPO | |
* | $75.0m | Private Placement VC | |
* | N/A | $173m | Post IPO Equity |
Total Funding | €170m |
Related Content
Recent News about Tourmaline Bio
EditTourmaline Bio is a biotechnology company focused on developing transformative medicines aimed at dramatically improving the lives of patients with life-altering immune diseases. The company operates in the biopharmaceutical market, targeting rare and significant unmet medical needs. Tourmaline Bio serves patients suffering from severe immune disorders, working closely with healthcare providers and research institutions. Their business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and approval of these therapies, followed by their commercialization either directly or through partnerships with larger pharmaceutical companies.
Keywords: biotechnology, immune diseases, transformative medicines, rare diseases, drug development, biopharmaceutical, healthcare, innovation, commercialization, research.